Acute hemodynamic effects of a selective serotonin reuptake inhibitor in postural tachycardia syndrome: A randomized,crossover trial

Abstract

Background:

Selective serotonin reuptake inhibitors (SSRIs) are often prescribed in patients with postural tachycardia syndrome (POTS), and act at synaptic terminals to increase monoamine neurotransmitters. We hypothesized that they act to increase blood pressure and attenuate reflex tachycardia, thereby improving symptoms. Acute hemodynamic profiles after SSRI administration in POTS patients have not previously been reported.

Methods:

Patients with POTS (n=39; F=37, 39 ±9 years) underwent a randomized crossover trial with sertraline 50mg and placebo. Heart rate, systolic, diastolic, and mean blood pressure were measured with the patient seated and standing for 10 min prior to drug or placebo administration, and then hourly for 4 h. The primary endpoint was standing heart rate at 4 h.

Results:

At 4 h, standing heart rate and systolic blood pressure were not significantly different between sertraline and placebo. Seated systolic (106±12 mmHg vs. 101±8 mmHg; p=0.041), diastolic (72±8 mmHg vs. 69±8 mmHg; p=0.022), and mean blood pressure (86±9 mmHg vs. 81±9 mmHg; p=0.007) were significantly higher after sertraline administration than placebo. At 4 h, symptoms were worse with sertraline than placebo.

Conclusions:

Sertraline had a modest pressor effect in POTS patients, but this did not translate into a reduced heart rate or improved symptoms.

Keywords

SSRI sertraline postural tachycardia syndrome blood pressure heart rate

Introduction

Postural tachycardia syndrome (POTS) is a chronic dysautonomia syndrome comprising symptoms of inadequate cerebral perfusion, dizziness, palpitations, altered mentation, fatigue, and sometimes syncope, when transitioning to an upright position (Robertson, 1999). The hallmark physiological feature is excessive orthostatic tachycardia. This condition is estimated to affect roughly half a million Americans, targeting mostly young women with a 4:1 ratio (Raj, 2006; Robertson, 1999).

Selective serotonin reuptake inhibitors (SSRIs) are drugs that are widely used for a number of psychiatric disorders. They work by inhibiting presynaptic monoamine reabsorption, thereby increasing monoamine neurotransmitters at the synaptic cleft, with resultant increased neurotransmission. While SSRIs primarily affect serotonin, other monoamine neurotransmitters such as norepinephrine and dopamine are also affected (Wong et al., 1993). Sertraline is a rapidly absorbed SSRI that has been shown in randomized placebo-controlled studies to be safe and efficacious in treating several psychiatric conditions, including major depressive disorder (Keller et al., 1998), obsessive compulsive disorder (Kronig et al., 1999), panic disorder (Londborg et al., 1998), post-traumatic stress disorder (Davidson et al., 2001), and premenstrual dysphoric disorder (Yonkers et al., 1997).

Sertraline has also been shown to be useful in the treatment of vasovagal syncope (Grubb et al., 1994). Perhaps due to the overlapping symptoms between vasovagal syncope and POTS, some experts have also recommended the use of sertraline for the treatment of POTS (Grubb, 2008; Kanjwal et al., 2011). The mechanism through which sertraline might benefit POTS patients is unclear. One possibility is that SSRIs could increase standing blood pressure (BP) and consequently decrease reflex tachycardia through inhibition of catecholamine reuptake (Goodnick and Goldstein, 1998a). Chronically administered sertraline did not produce significant hemodynamic changes in depressed patients (Scalco et al., 2009). There have been no studies that have evaluated the acute hemodynamic effects in patients with POTS. Conversely, short-term sertraline administration acutely suppressed sympathetic activity in healthy subjects (Stewart and Weldon, 2000). We tested the hypothesis that sertraline will induce a pressor response in patients with POTS, resulting in increased blood pressure, reduced reflex tachycardia and improved patient symptoms.

Methods

Subjects

Patients with POTS referred to the Vanderbilt University Autonomic Dysfunction Center between September 2007 and August 2011 were candidates for inclusion in this study. Patients met criteria for POTS in that they developed symptoms of orthostatic intolerance accompanied by a heart rate (HR) rise of >30 beats/min within 10 min of standing in the absence of orthostatic hypotension (a fall in BP of >20/10 mmHg) (Raj, 2006; Raj et al., 2005a; Schondorf and Low, 1993). All patients had at least a six-month history of symptoms in the absence of an additional chronic disorder known to cause orthostatic intolerance and in the absence of prolonged bed rest. All patients were at least 18 years old. The Vanderbilt University Investigational Review Board approved this study. Written informed consent was obtained from each subject before initiating the study. The data reported are a part of The Treatment of Orthostatic Intolerance study, which is registered with http://www.clinicaltrials.gov (NCT00262470).

Study diet and posture study

Study investigations were performed in the Elliot V Newman Clinical Research Center at Vanderbilt University. For at least three days before testing, subjects consumed a caffeine-free diet containing 150 mEq/d sodium and 60–80 mEq/d potassium. Long-term medications were discontinued five half-life periods before the study. HR, systolic BP (SBP), diastolic BP (DBP), and fractionated plasma catecholamines were measured after overnight rest with the patient in the supine position and again after standing for up to 30 min (as tolerated) as part of the posture study. For catecholamine measurements, blood was collected in plastic syringes, immediately transferred to chilled vacuum tubes with sodium heparin (BD, Franklin Lakes, NJ), and placed on ice. Plasma was separated by centrifugation at −4°C and stored at −70°C in collection tubes with 6% reduced glutathione (Sigma-Aldrich Inc., St Louis, MO) until the assay was performed. Concentrations of norepinephrine and epinephrine were measured by batch alumina extraction followed by high-performance liquid chromatography for separation with electrochemical detection and quantification (Jacob et al., 1997).

Medication trials

These “proof-of-concept” drug trials were started in the morning at least 2 h after an early, light breakfast (to avoid acute hemodynamic effects from eating) in a post-void state. Sertraline is a rapidly absorbed SSRI with peak concentrations at 4 h with a 50mg dose (Park et al., 2011). In this trial, patients with POTS were given sertraline hydrochloride 50mg (American Health Packaging, Columbus, OH) and placebo (“Cebocaps”; Forest Pharmaceuticals, New York, NY) in a randomized crossover fashion on separate days. The patients were seated in a chair during the data collection except during prescribed periods of standing. Seated rather than supine position was used in this study as this is the more clinically relevant posture for the patient. BP and HR were measured with an automated arm cuff vital signs monitor (Dinamap Vital Signs Monitor; Critikon Company, Tampa, FL) and digitally acquired into a custom-designed database (Microsoft Access, Microsoft Corporation, Redmond, WA). At time zero and hourly for 4 h after study drug administration, each patient was asked to stand for 10 min while standing HR and BP were recorded. The study was double-blinded, with the patient and the principal investigator blinded. Only the nurse administering the study drug was aware of its contents.

Symptoms

Patients were asked to self-report their symptom burden immediately before and at 2 and 4 h after study drug administration by using the Vanderbilt Orthostatic Symptom Score (Raj et al., 2005b). The patients were asked to rate the severity of nine symptoms on a scale of 0 to 10 (with 0 reflecting an absence of symptoms). The sum of the scores at each time point was used as a measure of symptom burden (lower score reflects reduced symptom burden). The nine symptoms were mental clouding, blurred vision, shortness of breath, rapid heartbeat, tremulousness, chest discomfort, headache, lightheadedness, and nausea. This symptom score has been used previously by our center (Coffin et al., 2012; Raj et al., 2005b, 2009a). These symptoms were chosen because they reflect common complaints of patients with POTS.

Statistical analysis

Our primary end point was the standing HR 4 h after study drug administration. The 4-h time point was chosen because the peak plasma concentration of sertraline occurs 4 h after dosing (Park et al., 2011). The null hypothesis was that the standing HR would not be statistically different between sertraline and placebo. The primary statistical analysis involved a paired t-test that compared the standing HR at 4 h after study drug administration between sertraline and placebo. Secondary analyses were performed with paired t-tests to compare the standing SBP and standing HR at the other hourly time points after study drug administration, the seated HR, delta HR (standing minus sitting), and BP values at each time point. Repeated-measures analysis of variance (ANOVA) was used to compare HR, SBP, and symptom score over time for the sertraline and placebo days; the Greenhouse–Geisser correction to the degrees of freedom from these analyses was used to adjust for failures of the sphericity assumption. Subgroup analysis of the primary outcome was performed based on posture study standing HR ≥ 120 beats/min or not and standing norepinephrine levels ≥ 600 pg/mL (3.54 nmol/L) or not. Our study had a power of 80% to detect a decrease in standing HR of 6.5 beats/min with a standard deviation for the difference of 14, based on conservative estimates from our previous studies in our main study population (Raj et al., 2009a).

Values are reported as means and standard deviations unless otherwise noted. Probability values ≤ 0.05 were considered statistically significant for the ANOVA, but a threshold of ≤ 0.25 was used for individual 2 h and 4 h paired tests due to the multiple comparisons. All tests were two-tailed. Statistical analyses were performed with SPSS for Windows (version 20.0, IBM Corporation, Armonk, NY). Prism for Windows 5 (version 5.02, GraphPad Software, Inc., La Jolla, CA) was used for graphical presentation.

Results

Baseline data and demographics

Study inclusion criteria were met by 39 patients with POTS (37 female; age 31±9 years). The data from the demographics and posture study are presented in Table 1. Upon standing from a supine position, the HR increased significantly from 74±11 beats/min to 118±26 beats/min (p<0.001), without a significant decrease in BP, consistent with the diagnosis of POTS. The mean supine plasma norepinephrine and epinephrine values were within the normal range (norepinephrine <475 nmol/mL and epinephrine <75 nmol/mL). Both plasma norepinephrine (1.46±1.53 nmol/mL vs. 4.57±3.09 nmol/mL; p<0.001) and plasma epinephrine (0.10±0.08 nmol/ml vs. 0.41±0.41 nmol/mL; p=0.040) increased significantly with standing. There were 19 patients with an excessively high standing HR (≥120 beats/min), and there were 19 patients with standing norepinephrine ≥600 pg/mL.

Table 1.

Demographics and posture study.

Total subjects (n)	39
Women (n)	37 (95%)
Age (years)	39 ± 9
Supine
Heart rate (beats/min)	74 ± 11
Systolic blood pressure (mmHg)	106 ± 12
Diastolic blood pressure (mmHg)	65 ± 8
Norepinephrine (nmol/mL)	1.46 ± 1.53
Epinephrine (nmol/mL)	0.10 ± 0.08
Standing
Heart rate (beats/min)	118 ± 26*
Systolic blood pressure (mmHg)	103 ± 22
Diastolic blood pressure (mmHg)	69 ± 16
Norepinephrine (nmol/mL)	4.57 ± 3.09*
Epinephrine (nmol/mL)	0.41 ± 0.41*
Change from supine to standing
Heart rate (beats/min)	45 ± 23
Systolic blood pressure (mmHg)	–3 ± 22
Diastolic blood pressure (mmHg)	4 ± 15
Norepinephrine (nmol/mL)	3.08 ± 2.92
Epinephrine (nmol/mL)	0.32 ± 0.43

Data are presented as mean ± standard deviation. Reported p values are for paired t-test comparing supine and upright parameters.

p < 0.001

Seated and standing HR

All 39 subjects underwent the paired administration of placebo and sertraline on different random days. The data for the drug trials are presented in Table 2. Immediately before administration of the study drug, there was no difference in seated HR between sertraline and placebo (89±12 beats/min vs. 86±12 beats/min; p=0.170). As seen in Figure 1(a), the seated HR decreased over time for both drugs, but sertraline did not decrease the seated HR significantly more than placebo over time (p_drug= 0.232).

Table 2.

Orthostatic hemodynamics and symptoms with sertraline 50mg and placebo in patients with postural tachycardia syndrome (n=39).

	Pre	Two hours	Four hours
Seated HR (beats/min)
Sertraline	89±12	82±11	80±12
Placebo	86±12	80±10	80±12
p value (between drugs)	0.165	0.166	0.912
Standing HR (beats/min)
Sertraline	115±17	108±16	102±17
Placebo	117±17	107±20	106±21
p value (between drugs)	0.312	0.913	0.167
Delta (standing – seated) HR (beats/min)
Sertraline	26±17	26±10	22±10
Placebo	31±12	27±14	25±14
p value (between drugs)	0.076	0.443	0.13
Seated SBP (mmHg)
Sertraline	100±8	100±10	106±12
Placebo	102±10	101±8	101±8
p value (between drugs)	0.086	0.87	0.041*
Standing SBP (mmHg)
Sertraline	104±11	106±12	111±13
Placebo	106±15	104±12	109±15
p value (between drugs)	0.397	0.277	0.244
Delta (standing – seated) SBP (mmHg)
Sertraline	4±9	6±12	6±15
Placebo	4±16	4±10	7±12
p value (between drugs)	0.076	0.443	0.13
Symptom score (AU) (n=35)
Sertraline	16±13	15±14	16±15
Placebo	20±18	14±13	13±11
p value (between drugs)	0.052	0.965	0.188

Repeated-measures analysis of variance (RM ANOVA) was used to determine the p value for the overall change between sertraline and placebo. The p values are reported for the drug effect (p_drug; sertraline vs. placebo). p-values were calculated using a two-tailed paired t-test. Delta values were calculated as the standing – seated values. Data are presented as mean ± standard deviation.

p<0.05 was considered significant.

HR: heart rate; SBP: systolic blood pressure; AU: arbitrary unit

Figure 1.

Heart rate and systolic blood pressure profiles of placebo and sertraline groups.

The standing HR (Figure 1(b)) before study drug administration was not significantly different between sertraline and placebo (115±18 beats/min vs. 117±17 beats/min; p=0.310). There was a significant decrease in standing HR over the 4-h period across both groups (p_time < 0.001), but no difference between sertraline and placebo over time (ANOVA p_drug = 0.437). The standing HR at 4 h post administration was no different between the sertraline group and the placebo group (102±17 beats/min vs. 106±20 beats/min; p=0.167).

The orthostatic tachycardia (Figure 1(c)), which is a cardinal feature of POTS, was similar at baseline between the sertraline and placebo groups (26±17 beats/min vs. 31±12 beats/min; p=0.076), and was not different after 4 h (22±10 beats/min vs. 26±14 beats/min; p=0.130).

Seated and standing BP

There were no differences between the sertraline and placebo days in seated SBP, seated DBP, or seated mean arterial BP (MAP) at baseline prior to the study. By 4 h, there was a trend toward higher BP in the sertraline group than placebo for seated MAP (86±9 mmHg vs. 81±9 mmHg; p=0.030; Figure 2(a)), seated SBP (106±12 mmHg vs. 101±8 mmHg; p=0.041; Figure 1(d)), and seated DBP (72±8 mmHg vs. 69±8 mmHg; p=0.022; Figure 2(d)). The seated SBP over time was not significantly different between sertraline and placebo (p_drug=0.600).

Figure 2.

Mean arterial blood pressure and diastolic blood pressure profiles of placebo and sertraline groups.

Baseline standing BP parameters were similar for sertraline and placebo. At 4 h post study drug, BP parameters were not different between the two groups. At 2 h, however, the standing MAP (111±13 mmHg vs. 89±11 mmHg; p=0.022) and the standing DBP (75±9 mmHg vs. 70±10 mmHg; p=0.003) were significantly higher on the sertraline day compared with the placebo day.

Orthostatic SBP between the sertraline and placebo groups was not significantly different at baseline (4±9 mmHg vs. 4±16 mmHg; p=0.080) or at 4 h, (6±15 mmHg vs. 7±12 mmHg; p=0.130).

Subgroup analysis

There were no significant differences in the standing SBP, DBP, and MAP, standing HR, or the orthostatic tachycardia between sertraline and placebo in any of the subgroups of patients (based on standing HR above or below 120 beats/min or standing norepinephrine levels above or below 600 pg/ml).

Symptoms

The symptom scores were completed for both placebo and sertraline days by 34 patients with POTS. The change in symptom score from baseline to 4 h was significantly different between the two days (Figure 3), with little change in the sertraline group, while the placebo group reported improved symptoms (0.25 ± 13 arbitrary units (AUs) vs. –7.69 ± 12 AU; p=0.010).

Figure 3.

Symptom profiles at baseline between placebo and sertraline groups.

Discussion

Acute hemodynamics effects of sertraline

Sertraline was associated with a trend toward increase in seated BP at 4 h compared with placebo, suggesting a sertraline induced pressor response, but this did not achieve statistical significance. Sertraline did not significantly elevate the standing SBP 4 h after its administration compared with placebo, and subsequently the standing HR at 4 h was also unchanged (which was our primary study end point). Unfortunately, sertraline did not improve symptoms acutely, and may have made symptoms worse.

The dose of sertraline used in this study was 50mg, but doses as high as 200mg/d are commonly used in clinical practice to treat some psychiatric disorders (Goodnick and Goldstein, 1998b). It is possible that higher doses of sertraline could affect beneficial hemodynamic changes in POTS patients. These potential benefits would have to be balanced against the potential increase in adverse effects associated with higher doses of sertraline, and requires further study.

The mechanism by which sertraline produces this pressor effect is unclear. In a study of depressed young males, the administration of serotonin chronically up to six weeks did not increase blood pressure significantly, but it did increase the serum levels of aldosterone and plasma renin activity (Ahmed et al., 2011). As we have shown earlier, individuals with POTS have paradoxically low aldosterone levels given their markedly reduced plasma volumes (Raj et al., 2005a). Therefore, it is plausible that sertraline is exerting its pressor response through the renin–aldosterone pathway, and this effect is more apparent in patients who have a baseline marked reduction in aldosterone levels, such as individuals with POTS.

POTS symptoms with sertraline

Standing HR decreased in both groups over time, which can be explained by diurnal variability, with an early morning peak in orthostatic and standing tachycardia (Brewster et al., 2012). Symptoms improved in the placebo group, but did not improve in the sertraline group. Possible explanations for the improvement in symptoms with placebo include diurnal variability or “placebo effect”, but the latter would not explain the less favorable response with sertraline.

Despite a potential pressor response, sertraline does not provide any immediate clinical improvement and may, in fact, worsen symptoms acutely. The reasons for this interesting finding are unclear, but could relate to the side-effect profile of this drug class, which is known to cause nausea, tremor, and dizziness (Beasley et al., 2000).

The patients in our study were exposed to sertraline acutely for four hours. In this acute setting, sertraline does not appear to improve the symptoms of POTS; however, the overall clinical benefit of using sertraline long-term in POTS patients is unknown, especially given that many POTS patients have symptoms that resemble anxiety (Raj et al., 2009b). The full therapeutic benefits of SSRIs for psychiatric disorders are not fully realized until after several weeks of daily administration. It has been reported that the neurotransmission of monoamines is further potentiated about 14 days after the initiation of treatment, when desensitization of pre-synaptic serotonin autoreceptors takes place (Goodnick and Goldstein, 1998a). Also, it has been shown that long-term administration of sertraline can blunt the effects of an overactive sympathetic nervous system (Scalco et al., 2009), which is a cardinal feature of POTS (Raj, 2006). Alternatively, there could be delayed potentiation of monoamine transmission with chronic SSRI administration. While the long-term administration of sertraline in a limited number of patients with major depressive disorder has not been shown to change BP (Scalco et al., 2009), the long term administration of sertraline in a small group of hemodialysis patients (n=9) over six weeks at doses of 50–100mg/d did improve the MAP (Dheenan et al., 1998). Similar long-term studies have not been performed in POTS patients (Scalco et al., 2009).

Norepinephrine transporter inhibition

Although sertraline selectively blocks serotonin reuptake at nerve terminals, it is also a weak inhibitor of the norepinephrine transporter. The short-term administration of sertraline has been shown to decrease circulating levels of norepinephrine in healthy patients (Shores et al., 2001). In addition, the long-term administration of sertraline has been shown to decrease muscle sympathetic nervous activity in depressed patients without POTS (Scalco et al., 2009). These two observations could explain why the standing BP failed to increase significantly with sertraline. Sertraline has marked affinity for the dopamine transporter (Goodnick and Goldstein, 1998a), and the observed elevation of seated BP might result from increased dopaminergic neurotransmission of adequate magnitude to affect seated but not standing BP.

Selective serotonin–norepinephrine versus SSRIs

Serotonin/norepinephrine reuptake inhibitors (SNRIs) are sometimes used in the management of POTS as second-line agents when more conventional medications such as fludrocortisone (Freitas et al., 2000), propranolol (Raj et al., 2009a), or midodrine (Jacob et al., 1997) either fail or cannot be tolerated. High-dose duloxetine can cause healthy volunteers to develop a POTS-like phenotype with increased orthostatic tachycardia after chronic administration that is likely related to norepinephrine transporter inhibition (Vincent et al., 2004). A more SSRI like sertraline, with less affinity for the norepinephrine transporter, might be better tolerated by POTS patients. Further studies need to be conducted to determine the utility of sertraline as a long-term agent for POTS.

Limitations

This study has several limitations. The sample size was relatively small, and therefore a small effect, albeit one of questionable clinical significance, may have been missed. Importantly, sertraline did not show a trend to improved symptoms, and was actually worse than placebo. This study used sertraline 50mg, and it is possible that larger doses might have yielded different results. Our patients were studied after a single administration of sertraline and then observed over 4 h. It is possible that with more prolonged administration, the pressor effects of sertraline would be accentuated and the increase in standing BP would be more evident. Typically, the psychiatric benefits of sertraline take several weeks to emerge. We did not find significant differences in any of our analyzed subgroups, although these analysis were not properly powered, and an effect cannot be excluded without a larger study. The overall clinical benefit of sertraline in POTS cannot be fully elucidated from this acute study focusing primarily on hemodynamic effects. This requires further, longer duration, studies, and these should ideally incorporate psychological measures.

Conclusion

The acute use of sertraline may be associated with a seated pressor response but did not increase standing BP or significantly reduce HR in POTS patients. Acute sertraline did not improve symptoms in POTS patients. Longer duration studies are needed to exclude a benefit of chronic sertraline therapy in this population.

Footnotes

Acknowledgements

We would like to thank our patients who participated in this project and to recognize the highly professional care provided by the staff of the Elliot V Newman Clinical Research Center.

Clinical trials registration

NCT00262470.

Conflict of interest

The authors declare that there is no conflict of interest.

Funding

This work was supported by the NIH (grant numbers R01HL102387, R01 HL071784, P01 HL56693) and the Clinical and Translational Science Award (grant number UL1TR000445).

References

Ahmed

Calvird

Gordon

(2011) Effects of two selective serotonin reuptake inhibitor antidepressants, sertraline and escitalopram, on aldosterone/renin ratio in normotensive depressed male patients. J Clin Endocrinol Metab 96: 1039–1045.

Beasley

Jr Koke

Nilsson

(2000) Adverse events and treatment discontinuations in clinical trials of fluoxetine in major depressive disorder: an updated meta-analysis. Clin Ther 22: 1319–1330.

Brewster

Garland

Biaggioni

(2012) Diurnal variability in orthostatic tachycardia: Implications for the postural tachycardia syndrome. Clin Sci (Lond) 122: 25–31.

Coffin

Black

Biaggioni

(2012) Desmopressin acutely decreases tachycardia and improves symptoms in the postural tachycardia syndrome. Heart Rhythm 9: 1484–1490.

Davidson

Rothbaum

van der Kolk

(2001) Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder. Arch Gen Psychiatry 58: 485–492.

Dheenan

Venkatesan

Grubb

(1998) Effect of sertraline hydrochloride on dialysis hypotension. Am J Kidney Dis 31: 624–630.

Freitas

Santos

Azevedo

(2000) Clinical improvement in patients with orthostatic intolerance after treatment with bisoprolol and fludrocortisone. Clin Auton Res 10: 293–299.

Goodnick

Goldstein

(1998a) Selective serotonin reuptake inhibitors in affective disorders – I. Basic pharmacology. J Psychopharmacol 12: S5–20.

Goodnick

Goldstein

(1998b) Selective serotonin reuptake inhibitors in affective disorders – II. Efficacy and quality of life. J Psychopharmacol 12: S21-S54.

10.

Grubb

(2008) Postural tachycardia syndrome. Circulation 117: 2814–2817.

11.

Grubb

Samoil

Kosinski

(1994) Use of sertraline hydrochloride in the treatment of refractory neurocardiogenic syncope in children and adolescents. J Am Coll Cardiol 24: 490–494.

12.

Jacob

Shannon

Black

(1997) Effects of volume loading and pressor agents in idiopathic orthostatic tachycardia. Circulation 96: 575–580.

13.

Kanjwal

Sheikh

Karabin

(2011) Neurocardiogenic syncope coexisting with postural orthostatic tachycardia syndrome in patients suffering from orthostatic intolerance: A combined form of autonomic dysfunction. Pacing Clin Electrophysiol 34: 549–554.

14.

Keller

Kocsis

Thase

(1998) Maintenance phase efficacy of sertraline for chronic depression: A randomized controlled trial. JAMA 280: 1665–1672.

15.

Kronig

Apter

Asnis

(1999) Placebo-controlled, multicenter study of sertraline treatment for obsessive-compulsive disorder. J Clin Psychopharmacol 19: 172–176.

16.

Londborg

Wolkow

Smith

(1998) Sertraline in the treatment of panic disorder. A multi-site, double-blind, placebo-controlled, fixed-dose investigation. Br J Psychiatry 173: 54–60.

17.

Park

Shin

Kim

(2011) Open label, three period, single sequence, study of 5, 25, 50 mg sertraline pharmacokinetics in healthy male Korean volunteers. Int J Clin Pharmacol Ther 49: 672–678.

18.

Raj

(2006) The postural tachycardia syndrome (POTS): Pathophysiology, diagnosis & management. Indian Pacing Electrophysiol J 6: 84–99.

19.

Raj

Biaggioni

Yamhure

(2005a) Renin–aldosterone paradox and perturbed blood volume regulation underlying postural tachycardia syndrome. Circulation 111: 1574–1582.

20.

Raj

Black

Biaggioni

(2005b) Acetylcholinesterase inhibition improves tachycardia in postural tachycardia syndrome. Circulation 111: 2734–2740.

21.

Raj

Black

Biaggioni

(2009a) Propranolol decreases tachycardia and improves symptoms in the postural tachycardia syndrome: Less is more. Circulation 120: 725–734.

22.

Raj

Haman

Raj

(2009b) Psychiatric profile and attention deficits in postural tachycardia syndrome. J Neurol Neurosurg Psychiatry 80: 339–344.

23.

Robertson

(1999) The epidemic of orthostatic tachycardia and orthostatic intolerance. Am J Med Sci 317: 75–77.

24.

Scalco

Rondon

Trombetta

(2009) Muscle sympathetic nervous activity in depressed patients before and after treatment with sertraline. J Hypertens 27: 2429–2436.

25.

Schondorf

Low

(1993) Idiopathic postural orthostatic tachycardia syndrome: An attenuated form of acute pandysautonomia? Neurology 43: 132–137.

26.

Shores

Pascualy

Lewis

(2001) Short-term sertraline treatment suppresses sympathetic nervous system activity in healthy human subjects. Psychoneuroendocrinology 26: 433–439.

27.

Stewart

Weldon

(2000) Vascular perturbations in the chronic orthostatic intolerance of the postural orthostatic tachycardia syndrome. J Appl Physiol 89: 1505–1512.

28.

Vincent

Bieck

Garland

(2004) Clinical assessment of norepinephrine transporter blockade through biochemical and pharmacological profiles. Circulation 109: 3202–3207.

29.

Wong

Bymaster

Reid

(1993) Norfluoxetine enantiomers as inhibitors of serotonin uptake in rat brain. Neuropsychopharmacology 8: 337–344.

30.

Yonkers

Halbreich

Freeman

(1997) Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment. A randomized controlled trial. Sertraline Premenstrual Dysphoric Collaborative Study Group. JAMA 278: 983–988.